Impact of a ketogenic diet on sleep quality in people with relapsing multiple sclerosis.

Background: Sleep disturbance in MS is common and can significantly impair overall quality of life. The ketogenic diet (KD) associates with improved sleep quality in people living with epilepsy and may have similar benefits when used within MS; however, the impact of a KD on sleep in this population remains poorly defined.

Methods: Forty-five patients with relapsing MS enrolled into a 6-month KD intervention trial and completed self-reported assessments of sleep quality and sleep disorder symptoms prior to diet initiation and while on diet, using the Epworth Sleepiness Scale (ESS) and Sleep Disorders Symptom Checklist-25 (SDS).

Ketogenic diet in relapsing multiple sclerosis: Patient perceptions, post-trial diet adherence & outcomes.

Background: Ketogenic diets (KDs) are safe and tolerable in people with multiple sclerosis (MS). While many patient-reported and clinical benefits are noted, the sustainability of these diets outside of a clinical trial is unknown.

Aims: Evaluate patient perceptions of the KD following intervention, determine the degree of adherence to KDs post-trial, and examine what factors increase the likelihood of KD continuation following the structured diet intervention trial.

Serum neurofilament light chain in relapsing multiple sclerosis patients on a ketogenic diet.

Background: Ketogenic diets have anti-inflammatory and neuroprotective properties which make these diets an attractive complimentary treatment approach for patients living with multiple sclerosis (MS). The objective of this study was to assess the impact of ketogenic diets on neurofilament light chain (NfL), a biomarker of neuroaxonal injury.

Methods: Thirty-nine subjects with relapsing MS completed a 6-month ketogenic diet intervention.

Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits.

Background: Dietary changes impact human physiology and immune function and have potential as therapeutic strategies.

Objective: Assess the tolerability of a ketogenic diet (KD) in patients with relapsing multiple sclerosis (MS) and define the impact on laboratory and clinical outcome metrics.

Methods: Sixty-five subjects with relapsing MS enrolled into a 6-month prospective, intention-to-treat KD intervention.

Pilot study of a ketogenic diet in relapsing-remitting MS.

Objective: To assess the safety and tolerability of a modified Atkins diet (KD), a type of ketogenic diet (KD), in subjects with relapsing MS while exploring potential benefits of KDs in MS.

Methods: Twenty subjects with relapsing MS enrolled into a 6-month, single-arm, open-label study of the KD. Adherence to KD was objectively monitored by daily urine ketone testing.